|
|
|
| Advances in the treatment of AIDS complicated with tuberculosis |
| WEI Huaying YANG Yang ZENG Jing WU Yongfeng HUA Wei GUO Caiping ZHANG Yulin▲ |
| Department of Infectious Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China |
|
|
|
Abstract Tuberculosis (TB) is one of the leading opportunistic infections and causes of death among people infected with the human immunodeficiency virus. The treatment of AIDS patients with tuberculosis (AIDS) is complicated by the fact that antiretroviral (ART) drugs and anti-TB drugs may have similar metabolic and elimination pathways. Therefore, the choice of treatment drugs for coinfected persons is very important. This article will briefly describe the progress of treatment regimens, drug interactions and drug hepatotoxicity in AIDS patients with TB.
|
|
|
|
|
|
[1] WHO Guidelines Approved by the Guidelines Review Committee [A]. In：WHO consolidated guidelines on tuberculosis：tuberculosis preventive treatment：Module 1：prevention. Geneva：World Health Organization（c） World Health Organization 2020，2020.
[2] 中华医学会感染病学分会艾滋病学组，中华医学会热带病与寄生虫学分会艾滋病学组.HIV合并结核分枝杆菌感染诊治专家共识[J].中华临床感染病杂志，2017，10（2）：81-90.
[3] Hamada Y，Ford N，Schenkel K，et al. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment：a systematic review [J]. Int J Tuberc Lung Dis，2018，22（12）：1422-1428.
[4] Westreich DJ，Sanne I，Maskew M，et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy [J]. Clin Infect Dis，2009，48（11）：1617-1623.
[5] Mudzviti T，Shamu T，Chimbetete C，et al. Tolerability of Isoniazid Preventive Therapy in an HIV-Infected Cohort of Paediatric and Adolescent Patients on Antiretroviral Therapy from a Resource-Limited Setting：A Retrospective Cohort Study [J]. Drugs Real World Outcomes，2019，6（1）：37-42.
[6] Dheda K，Lampe FC，Johnson MA，et al. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy [J]. J Infect Dis，2004，190（9）：1670-1676.
[7] 中华医学会感染病学分会艾滋病丙型肝炎学组，中国疾病预防控制中心.中国艾滋病诊疗指南（2018年版）[J].中华内科杂志，2018，57（12）：867-884.
[8] Onyebujoh P，Zumla A，Ribeiro I，et al. Treatment of tuberculosis：present status and future prospects [J]. Bull World Health Organ，2005，83（11）：857-865.
[9] Pettit AC，Shepherd BE，Sterling TR. Treatment of drug-susceptible tuberculosis among people living with human immunodeficiency virus infection：an update [J]. Curr Opin HIV AIDS，2018，13（6）：469-477.
[10] Nahid P，Mase SR，Migliori GB，et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline [J]. Am J Respir Crit Care Med，2019，200（10）：e93-e142.
[11] Mallikaarjun S，Wells C，Petersen C，et al. Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects [J]. Antimicrob Agents Chemother，2016，60（10）：5976-5985.
[12] 中华医学会结核病学分会.中国耐多药和利福平耐药结核病治疗专家共识（2019年版）[J].中华结核和呼吸杂志，2019，42（10）：733-749.
[13] Rae JM，Johnson MD，Lippman ME，et al. Rifampin is a selective，pleiotropic inducer of drug metabolism genes in human hepatocytes：studies with cDNA and oligonucleotide expression arrays [J]. J Pharmacol Exp Ther，2001， 299（3）：849-857.
[14] Maartens G，Decloedt E，Cohen K. Effectiveness and safety of antiretrovirals with rifampicin：crucial issues for high-burden countries [J]. Antivir Ther，2009，14（8）：1039-1043.
[15] Li AP，Reith MK，Rasmussen A，et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics：evaluation of rifampin，rifapentine and rifabutin [J]. Chem Biol Interact，1997，107（1/2）：17-30.
[16] Davies G，Cerri S，Richeldi L. Rifabutin for treating pulmonary tuberculosis [J]. Cochrane Database Syst Rev，2007（4）：Cd005159.
[17] Gonzalez-Montaner LJ，Natal S，Yongchaiyud P，et al. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis：a multinational，randomized，comparative study versus Rifampicin. Rifabutin Study Group [J]. Tuber Lung Dis，1994，75（5）：341-347.
[18] Boulle A，Van Cutsem G，Cohen K，et al. Outcomes of nevirapine-and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy [J]. JAMA，2008，300（5）：530-539.
[19] Lopez-Cortes LF，Ruiz-Valderas R，Viciana P，et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis [J]. Clin Pharmacokinet，2002，41（9）：681-690.
[20] Cohen K，Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment [J]. Curr Opin HIV AIDS，2010，5（1）：61-69.
[21] Gulick RM，Ribaudo HJ，Shikuma CM，et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection [J]. N Engl J Med，2004，350（18）：1850-1861.
[22] Wenning LA，Hanley WD，Brainard DM，et al. Effect of rifampin，a potent inducer of drug-metabolizing enzymes，on the pharmacokinetics of raltegravir [J]. Antimicrob Agents Chemother，2009，53（7）：2852-2856.
[23] Abel S，Jenkins TM，Whitlock LA，et al. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers [J]. Br J Clin Pharmacol，2008，65 Suppl 1：38-46.
[24] Patel IH，Zhang X，Nieforth K，et al. Pharmacokinetics，pharmacodynamics and drug interaction potential of enfuvirtide [J]. Clin Pharmacokinet，2005，44（2）：175-186.
[25] Puri P，Kaur N，Pathania S，et al. Antitubercular therapy induced liver function tests abnormalities in human immunodeficiency virus infected individuals [J]. Med J Armed Forces India，2017，73（1）：12-17.
[26] 中华医学会结核病学分会.抗结核药物性肝损伤诊治指南（2019年版）[J].中华结核和呼吸杂志，2019，42（5）：343-356.
[27] Schutz C，Meintjes G，Almajid F，et al. Clinical management of tuberculosis and HIV-1 co-infection [J]. Eur Respir J，2010，36（6）：1460-1481. |
|
|
|
